SepsiTest enables detection of over 345 germs within a few hours.

Molzym received European market approval for its diagnostic kit for sepsis, SepsiTest™. The product is a PCR-based test that can detect more than 345 relevant sepsis germs in less than four hours. This is a significant improvement over the current culture methods that take, on average, 48 hours.


Blood cultures are limited when detecting fastidious organisms or when antibiotic therapies have already been administered. As for other molecular diagnostics, “Roche Diagnostics recently launched a test called Septifast. This test detects only 25 bacteria,” according to Jan Detmers, director business development.


SepsiTest will cost €81.50, says Detmers. According to European in vitro diagnostic law, SepsiTest can be marketed in the following countries since it has the CE-IVD-marking: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania, Spain, Slovakia, Slovenia, Sweden, and the U.K.

Previous articleBayer to Build On Kentucky Bioproccessing’s Facility for Plant-Made Biopharmaceutical Production
Next articleLink Medicine Obtains $40M in Series C Round to Further its Neurodegenerative Preclinical Pipeline